Lundbeck, Alder negotiated ex-U.S. deal before opting for takeout

After soliciting offers from multiple parties to obtain ex-U.S. rights to its migraine treatment, Alder continued to negotiate such a deal with Lundbeck -- while also working out an outright acquisition offer the biotech would accept instead, according to a new regulatory document.

Rather than take an

Read the full 463 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers